Dawson James analyst Jason Kolbert said that a New York Times article on Friday suggesting that the Biomedical Advanced Research and Development Authority, or BARDA,...
JPMorgan analyst Paul Coster initiated coverage of Nikola with a Neutral rating and $45 price target. The stock in premarket trading is down 3.5%, or...
KeyBanc analyst Donald Hooker raised the firm's price target on Livongo Health to $85 from $52 and reiterates an Overweight rating on the shares. The...
Barclays analyst Carter Gould downgraded Biogen to Equal Weight from Overweight with a price target of $280, down from $370. The district court decision that...